Celgene surges on positive PhIII myeloma data for Revlimid; ALK reports PhIII success for allergy pill; Is fish oil bad for you?;

Biotech News

@FierceBiotech: 2013 Biotech IPOs: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Deborah Dunsire makes quick leap from Millennium to fast-growing EnVivo. News | Follow @JohnCFierce

 @RyanMFierce: Alnylam Pharma spotlights more upbeat human data or gene-silencing drugs. Story | Follow @RyanMFierce

 @EmilyMFierce: Anti-leukemia compound could also treat common breast cancers. Story | Follow @EmilyMFierce

> Shares of Celgene ($CELG) shot up this morning after the company reported that Revlimid produced promising data in a study for multiple myeloma. And now it's preparing to file for an expanded approval of the therapy. Story

> Denmark's ALK (OMX: ALK.B) says it reaped positive data from the second of two pivotal Phase III trials of its new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases. Release

> Sorrento Therapeutics and researchers at Israel's Ben-Gurion University of the Negev are partnering to develop anti-hepatitis C antibodies. Report

Medical Device News

 @FierceMedDev:  ICYM this week's M&A feature - Blockbusters and bloodlettings: A look at 2013's hot start. Special report | Follow @FierceMedDev

 @MarkHFierce: Only a few weeks left to nominate a company for this year's FMD Fierce 15. Submit your nomination | Follow @MarkHFierce

 @DamianFierce: Device outfit CVRx has raised $29.6M in a round led by NEA and J&J. Article | Follow @DamianFierce

> Report: Baxter's $4B bid for Gambro to win EU approval. More

> Stentys' self-apposing cardiac stent gains expanded CE mark indications. Item

> VisionCare discloses CMS coverage plan for implantable miniature telescope. Story

> Myriad targets Gene By Gene in second BRCA patent suit. Report

Pharma News

 @FiercePharma: Pharma, FDA still lag in post-marketing safety studies. Getting better, but large % unfinished--or not begun. Yesterday's story | Follow @FiercePharma

 @CarlyHFierce: NICE says 'no' to Celgene's Revlimid. Article | Follow @CarlyHFierce

> U.K. recalls 16 Wockhardt drugs, bans products from Indian plant. Report

> New problems for GSK in China as authorities say GSK employees confess to bribery. News

> Vivus hooks up with Menarini to hawk ED pill Spedra in $121M deal. More

Pharma Manufacturing News

 @EricPFierce: BioPlan says China, India losing luster for outsourced biopharmaceutical manufacturing. More | Follow @EricPFierce

> Wockhardt faces 2nd import alert. Report

> Sanofi's ImmuCyst available in next year, Alliance Pharma says. More

> Pfizer to invest $130M in 2 plants in Ireland. News

> Contract manufacturer Piramal also into development, cellphones. Story

Vaccines News

> Manufacturers prepare for resurgence of H7N9. News

> Robot eases kids' vaccination distress in study. More

> Novartis inks typhoid vax licensing deal with Biological E. Story

> U.K. mumps outbreak linked to waning MMR protection. Report

And Finally… A new study finds that men with high concentrations of omega-3 fish oil in their blood suffered a significantly higher risk of prostate cancer, despite a range of earlier studies that found it has a tonic effect on people's health. Story

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.